Should You Diet Before Starting Tirzepatide? What the SURMOUNT-3 Lifestyle Trial Shows

Many people who ask about tirzepatide have already spent years on diets that worked for a while and then stalled, so a common question at a telehealth visit is whether it is better to diet first and add tirzepatide later.

One randomized trial was built to test exactly this sequence. SURMOUNT-3, published by Wadden and colleagues in Nature Medicine in 2023, put adults with overweight or obesity through a 12 week intensive lifestyle program before randomizing those who succeeded to tirzepatide or placebo.

What did the SURMOUNT-3 trial test?

SURMOUNT-3 tested whether tirzepatide could add meaningful weight loss in people who had already lost weight through an intensive diet and activity program. The trial enrolled 806 adults with a body mass index of 30 or higher, or 27 or higher with at least one weight related condition and excluded people with diabetes.

Every participant first completed a 12 week lifestyle phase. Women were asked to eat about 1,200 kcal per day and men about 1,500 kcal per day, with the option of up to two meal replacements daily, and everyone was encouraged to reach at least 150 minutes of moderate activity such as brisk walking each week. A dietitian led eight counseling sessions over those 12 weeks.

Only people who lost at least 5% of their starting weight moved on. Those 579 participants, 71.8% of the people enrolled, were randomized to their maximum tolerated dose of tirzepatide (10 or 15 mg once weekly) or to placebo for 72 weeks, with lifestyle visits continuing on a quarterly schedule.

How much weight did people lose before starting tirzepatide?

The randomized participants lost an average of 6.9% of body weight during the 12 week lifestyle phase, falling from 109.5 kg to 101.9 kg. That loss of about 7.6 kg came with measurable health changes: waist circumference fell by 6.7 cm on average and systolic blood pressure by 5.0 mmHg.

These figures describe only the people who succeeded in a supervised, calorie controlled program, which is far more demanding than casual dieting.

Does tirzepatide work after a diet has already taken weight off?

Yes, in SURMOUNT-3 tirzepatide produced large additional weight loss after the diet phase. From randomization to week 72, weight changed by an additional 18.4% reduction in the tirzepatide group and by a 2.5% gain in the placebo group, a difference of 20.8 percentage points.

This addresses a common worry that a body which has just dieted will resist further loss, since the authors note that regain after dieting is driven partly by rising hunger hormones and falling energy expenditure. For background, see what metabolic chamber studies show about tirzepatide and energy expenditure.

What happened to people who dieted and then took placebo?

Participants who completed the diet phase and then received placebo regained weight on average. Their weight rose 2.5% from randomization to week 72, and only 43.8% kept at least 80% of the weight they had lost during the lifestyle phase, compared with 94.0% of the tirzepatide group.

Quarterly lifestyle visits continued for the placebo group, but the authors note this was much lighter than the 17 sessions in an earlier liraglutide trial and may explain part of the regain. The maintenance phase raises the same question later in treatment.

Is dieting before tirzepatide better than starting it right away?

SURMOUNT-3 cannot answer that question, because every randomized participant dieted first and no group started tirzepatide without a diet phase. The trial shows that tirzepatide added substantial loss after a successful diet, but it does not show that the diet first route beats starting the medication on day one.

The numbers invite a comparison with SURMOUNT-1, where adults without diabetes took tirzepatide with standard lifestyle advice and no intensive diet phase. In that trial, weight fell by 20.9% on 15 mg and 19.5% on 10 mg at 72 weeks, compared with the total reduction of 24.3% from the start of the lifestyle phase in SURMOUNT-3. The SURMOUNT-3 authors themselves caution that the larger total may reflect who was selected, since only people who responded to the diet were randomized, and they write that participants who respond to lifestyle intervention may simply be more responsive to tirzepatide.

Running diet and medication together has also been tested: in STEP 3, semaglutide 2.4 mg combined with a low calorie diet and intensive counseling lowered weight by 16.0% compared with 5.7% on placebo at 68 weeks, but that design differs too much from SURMOUNT-3 to settle which order works best.

How does SURMOUNT-3 compare with earlier diet first trials?

The same design had been used with liraglutide, a daily GLP-1 medication: in the SCALE Maintenance trial, 422 participants lost 6.0% of their weight on a low calorie diet, then took liraglutide 3.0 mg or placebo for 56 weeks. Liraglutide produced an additional 6.2% loss compared with 0.2% on placebo, and 81.4% of liraglutide participants kept their diet phase loss compared with 48.9% on placebo.

In both trials, medication after a diet protected the earlier loss and added to it, although differences in drugs, durations and counseling mean the gap is not a direct ranking.

Are side effects different when tirzepatide follows a diet?

Gastrointestinal side effects were the most common problem in SURMOUNT-3, as in other tirzepatide trials, and most were mild to moderate and occurred during dose escalation. Nausea was reported by 39.7% of tirzepatide participants and 14.0% on placebo, diarrhea by 31.0% and 9.2%, constipation by 23.0% and 6.8%, and vomiting by 18.1% and 1.4%.

Side effects led 10.5% of tirzepatide participants to stop treatment, compared with 2.1% on placebo. The authors describe these rates as modestly higher than in the 15 mg group of SURMOUNT-1, where 6.2% stopped for adverse events, and note that other trials pairing intensive lifestyle programs with medication have also shown more gastrointestinal events. Why this happens has not been established. Practical steps for the most common symptom are covered in our guide to tirzepatide nausea.

A very low intake combined with appetite suppression can also crowd out protein and micronutrients, so the warning signs in eating too little on tirzepatide are worth reviewing with a clinician.

Does a diet first phase improve how people feel?

A 2025 SURMOUNT-3 analysis by Gibble and colleagues in Diabetes, Obesity and Metabolism found that tirzepatide was associated with significantly larger improvements than placebo in most health related quality of life measures after the diet phase. Gains were generally larger with greater weight loss. This analysis was also manufacturer funded.

What are the limits of the SURMOUNT-3 evidence?

Several limits shape how far SURMOUNT-3 can be applied. The 17.5% of participants who did not lose 5% during the lifestyle phase were never randomized, so the trial says nothing about people who diet without success, and the authors acknowledge this may have pushed the average result higher. The study population was mostly white and limited to the Americas, and the trial was sponsored by Eli Lilly, which makes tirzepatide.

Animal work is suggestive but not proof: in a 2024 Molecular Metabolism study, obese mice given 7 or 14 days of calorie restriction before semaglutide or tirzepatide lost more weight than mice that started without it, and no human trial has randomized diet first against medication first. SURMOUNT-3 also says nothing about stopping tirzepatide; see weight regain after stopping GLP-1 therapy.

What does this mean for someone considering tirzepatide?

For people who have recently lost weight through a structured program, SURMOUNT-3 suggests tirzepatide can help protect and extend that loss. For people who have not dieted first, the trial gives no reason to think a mandatory diet phase is required, because that comparison was never made, and the Zepbound prescribing information lists use in combination with a reduced calorie diet and increased physical activity in any case.

Decisions about timing, calorie targets and dose escalation belong with a licensed clinician who knows the full history, including any disordered eating. Individual results vary, and the titration ladder still applies whether or not someone has dieted first.

Frequently asked questions